Accent Capital Management LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,575 shares of the medical research company's stock, valued at approximately $836,000. Thermo Fisher Scientific comprises about 0.7% of Accent Capital Management LLC's investment portfolio, making the stock its 27th largest position.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Sugarloaf Wealth Management LLC boosted its position in Thermo Fisher Scientific by 6.9% in the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company's stock worth $156,000 after purchasing an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton boosted its position in Thermo Fisher Scientific by 3.7% in the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company's stock worth $279,000 after purchasing an additional 19 shares during the last quarter. Tsfg LLC lifted its position in shares of Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company's stock valued at $132,000 after buying an additional 19 shares in the last quarter. Pacifica Partners Inc. lifted its position in shares of Thermo Fisher Scientific by 16.5% during the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company's stock valued at $69,000 after buying an additional 20 shares in the last quarter. Finally, Foundations Investment Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 1,069 shares of the medical research company's stock valued at $591,000 after buying an additional 20 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $70,873,516.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $70,873,516.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock valued at $12,532,780 in the last quarter. 0.34% of the stock is owned by insiders.
Thermo Fisher Scientific Trading Down 0.7 %
- 16 Top Robotics Companies to Get to Know in 2023
NYSE:TMO traded down $4.05 during midday trading on Monday, hitting $568.00. 1,278,122 shares of the company traded hands, compared to its average volume of 1,486,867. The firm's fifty day moving average is $574.95 and its 200-day moving average is $559.33. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The firm has a market capitalization of $216.82 billion, a P/E ratio of 36.43, a P/E/G ratio of 2.67 and a beta of 0.79. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
- Agilent Technologies Stock: Ready to Rise off the Floor
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.01%.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the company. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. HSBC lifted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a research report on Tuesday, April 30th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research report on Thursday, April 25th. Evercore ISI boosted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a report on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a "buy" rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $607.94.
Read Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
(Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Energy and Oil Stocks Explained
- Buffett Bails on BYD: What It Means forthe Future of EV Stocks
- Using the MarketBeat Dividend Tax Calculator
- Domino’s vs. Papa John's: Stock Showdown of Pizza Giants
- Dividend Payout Ratio Calculator
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Catalyst Could Trigger 10,000% Crypto Gains (From Crypto 101 Media) (Ad)
Should you invest $1,000 in Thermo Fisher Scientific right now?
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
12 Stocks Corporate Insiders are Abandoning
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
